Interesting, eh? Will we see RCPI react to this news?
What attention will it bring to market activity on RCPI?
From the news release...
"... The primary objective of the study was to determine whether a single dose of orally administered anatabine citrate could reduce the activation of inflammatory proteins in human white blood cells."
Results, from the news release...
"... Data analysis showed that there were statistically significant (p
Investors are actually dumb enough to respond to the short's nasty postings keeping their nasty headliners on top.
I'm not an expert in all this but I would think because the brokers/mm's covered the private placement shares based on today's volume that we should see an upward climb as the shorts and others buy at this low price range and will be chasing the share price back up. New money should stir new activity, yes? :)
Onward and upward, where will RCPI close today, 2.83+?...
It's a private placement form of financing so I don't think it's added to the float? They may be accommodating the volume, but, the share price may be only affected until the volume is accommodated? Well, not an expert so we'll see what happens when the volume exceeds 1.645 mln?
Target volume is around 1.645 mln, I think, then they may walk the share price back up to around 2.80+ or higher. Not an expert at this so just an opinion....
Buy the cheap shares while the share price is below 2.25 because they'll be walking the price back upabve that target when the shares are sold above 1.6 mln. I think this is how it works, not an expert so just an opinion...
UK Clinical Trial Phase I:
".... As of June 1, 2015, Part One of the Phase I study is complete, and the Company announces that there were no reports of serious adverse events (AEs) or AEs leading to study withdrawal. Further, there were no safety concerns raised by either the Company's UK contract research organization or its UK based trial medical monitor.
The Company now expects to conduct Part Two of the study primarily to evaluate the effects of food on PK parameters. Dosing in Part Two is expected to commence and be completed within the third quarter 2015.
Subsequently, the Company expects to conduct Part Three of the study comprised of a double-blind, placebo-controlled, seven-day multiple dose study of the optimal formulation in healthy subjects and is targeting study completion and generating preliminary results in the third quarter 2015. It is anticipated that follow up data management and analysis will be completed during the fourth quarter 2015. As per the trial design, outcome measures will focus primarily on overall safety and tolerability with secondary measures focusing on standard PK parameters and also PD assessment, specifically measuring the impact of the drug on inflammatory processes."
New Zealand Study:
"... The primary outcome measure of the study was a pharmacodynamic assessment of whether a single dose of orally administered anatabine citrate can acutely attenuate expression and/or production of pro-inflammatory mediators in human white blood cells, thus creating an anti-inflammatory effect. Follow up analysis is complete and the Company is expecting to provide a formal report in the third quarter. "
Sounds like they're making more definitive advancements. You say this information was published on May 26th?